Symbols

BGMS

Bio Green Med·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BGMS

Bio Green Med Solution, Inc.

A company actively exploring in the fields of biomedicine and green technology

Industry

Biological Technology

Established Date

Listing Date

03/16/2004

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cyclacel.com

Security Type

Common stock

Office address

Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi, Kuala Lumpur, Malaysia 592000

Business

Introduction

Bio Green Med Solution, Inc., a biopharmaceutical company established in 1996 and in the development stage, is dedicated to the development and commercialization of new and organ-related drugs for the treatment of human cancer and other critical diseases. Bio Green Med is a pioneer in the field of cell cycle, which dares to treat patients with new drugs that are only suitable for oral use. Its goal is to become a diversified biomedical company focusing on hematological and oncology research based on the development of its series of commercial products and new drug screening mechanisms. As a developing company, all the company's efforts contribute to its research and development, guide clinical trials, develop and acquire new intellectual property, improve capital reserves and profitability, and train employees. Its goal is to develop and commercialize small molecule drugs for the control of all stages of the cell cycle and for the treatment of cancer and other major diseases, especially those areas with large medical gaps.

Company Financials

EPS

BGMS has released its 2025 Q3 earnings. EPS was reported at -1.31, versus the expected -72, beating expectations. The chart below visualizes how BGMS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BGMS has released its 2025 Q3 earnings report, with revenue of 81.00K, reflecting a YoY change of 710.00%, and net profit of -988.00K, showing a YoY change of 49.51%. The Sankey diagram below clearly presents BGMS's revenue sources and cost distribution.